NanoCarrier Co., Ltd. (4571) AI Stock Analysis

• Market Cap: ¥11.83B
• Dividend Yield: N/A
• Average Volume (3M): 2.35M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.89
• Revenue Growth: 172.39%
• EPS Growth: 8.27%
• Country: JP
• Employees: 18
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -2.86
• Shares Outstanding: 75,374,160
• 10 Day Avg. Volume: 484,410
• 30 Day Avg. Volume: 2,345,523
• PEG Ratio: -1.80
• Price to Book (P/B): 3.71
• Price to Sales (P/S): 93.58
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: ¥159.00 ▲(18.66% Upside)
• Action: Upgraded Date: 02/28/26
• Date: Action: Upgraded 02/28/26

The score is held back primarily by weak financial performance (shrinking revenue, large ongoing losses, and continued cash burn). Technical momentum is a meaningful offset with the stock trading above major moving averages and positive MACD, while valuation remains constrained by negative earnings and no dividend.

Positive Factors

High Gross Margins

A ~72% gross margin indicates the underlying DDS formulations have strong unit economics and potential for high-margin licensing or manufacturing. Once fixed R&D and SG&A spend are controlled or shifted to partners, this margin supports sustainable profitability and attractive royalties over time.

Negative Factors

Persistent Cash Burn

Consistent negative operating cash flow forces reliance on financing, asset sales, or dilutive capital raises to fund R&D and operations. This structural cash burn limits independent development capacity, increases financing costs or dilution risk, and constrains strategic flexibility over the coming months.

NanoCarrier Co., Ltd. Business Overview & Revenue Model

Company Description

NANO MRNA Co., Ltd. engages in the research, development, and production of pharmaceuticals using micellar nanoparticles technology. The company develops biopharmaceutical products focused on the medication of cancer and other intractable diseases...

Read more

NANO MRNA Co., Ltd. engages in the research, development, and production of pharmaceuticals using micellar nanoparticles technology. The company develops biopharmaceutical products focused on the medication of cancer and other intractable diseases...

How the Company Makes Money

NanoCarrier’s earnings are primarily tied to monetizing its drug delivery technology and associated drug candidates through (1) collaboration/licensing arrangements and (2) development-related consideration tied to partnered programs. In practice,...

Read more

NanoCarrier’s earnings are primarily tied to monetizing its drug delivery technology and associated drug candidates through (1) collaboration/licensing arrangements and (2) development-related consideration tied to partnered programs. In practice,...

NanoCarrier Co., Ltd. Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	116.22M	108.52M	135.51M	202.19M	264.03M	313.26M
Gross Profit	84.46M	78.17M	110.96M	159.60M	220.88M	274.88M
EBITDA	-755.92M	-755.33M	-863.31M	-1.25B	-2.06B	-1.30B
Net Income	-880.20M	-835.38M	-780.00M	-1.31B	-1.88B	-2.84B
Balance Sheet
Total Assets	3.93B	4.00B	5.07B	5.78B	7.14B	7.82B
Cash, Cash Equivalents and Short-Term Investments	3.40B	3.51B	4.28B	4.44B	5.95B	6.40B
Total Debt	540.24M	540.24M	1.11B	1.11B	1.15B	0.00
Total Liabilities	1.28B	1.26B	1.65B	1.53B	1.57B	321.00M
Stockholders Equity	2.66B	2.74B	3.42B	4.25B	5.57B	7.50B
Cash Flow
Free Cash Flow	0.00	0.00	-585.08M	-1.09B	-1.76B	-1.25B
Operating Cash Flow	0.00	-401.62M	-585.08M	-1.09B	-1.75B	-1.25B
Investing Cash Flow	0.00	587.53M	793.01M	1.21B	-244.13M	-871.69M
Financing Cash Flow	0.00	-568.77M	3.73M	32.20M	1.15B	-11.46M

NanoCarrier Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 134.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4571, the sentiment is Negative. The current price of 134 is below the 20-day moving average (MA) of 162.05, below the 50-day MA of 159.14, and below the 200-day MA of 150.73, indicating a neutral trend. The MACD of -3.40 indicates Positive momentum. The RSI at 43.32 is Neutral, neither overbought nor oversold. The STOCH value of 16.16 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4571.

NanoCarrier Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4888	60 Neutral	¥23.48B	-8.45	―	―	248.15%	76.92%
4588	55 Neutral	¥75.68B	-20.18	―	―	-9.04%	13.09%
4571	52 Neutral	¥11.83B	-12.44	-26.70%	―	172.39%	8.27%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4563	47 Neutral	¥22.99B	-4.22	-184.71%	―	56.75%	-97.56%
4583	47 Neutral	¥7.56B	-7.39	―	―	25.28%	39.15%
4564	46 Neutral	¥10.36B	-7.89	-63.25%	―	99.87%	40.60%

NanoCarrier Co., Ltd. Corporate Events